Abstract
The arrival of recombinant insulin in the pharmaceutical market paved a new direction for the clinical potential of proteins. Thus, the pharmaceutical industry underwent a paradigm shift towards proteins as therapeutic moieties. A number of recombinant protein drugs are available and many more are in pipeline to target major diseases, such as cancer, viral diseases, cardiovascular diseases and endocrine diseases.
Highlights
The arrival of recombinant insulin in the pharmaceutical market paved a new direction for the clinical potential of proteins
As in case of growth hormone (GH) therapy, where administration of the growth hormone in patients with severe GH deficiency and hypopituitarism was found to be safe for long- and short-term usage [3,4]
Li and colleagues reported anti-tumor effect of novaferon, a novel recombinant protein produced by DNA shuffling of interferon-α [7]
Summary
The arrival of recombinant insulin in the pharmaceutical market paved a new direction for the clinical potential of proteins. In terms of cancer protein therapeutics, currently only monoclonal antibodies, targeting over-expressed receptors, are prominently available for treatment of different tumors. The clinical success and the long-term benefits of recombinant protein therapy for treatment of several diseases have fostered enormous interest in their application for treatment of cancer.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
